Margaret O’Keefe Glavin, who has been chief of regulatory affairs since 2005, is about to leave after 40 years of working for the federal government, Dow Jones reports. Although not a household name, she was among FDA officials singled out by lawmakers who chastised the agency for paying outsized bonuses. She was previously an assistant commish for counterterrorism planning at the FDA.

Last year, after Congress demanded compensation details about top FDA officials, Glavin reportedly received more than $178,000 in bonuses in four and a half years on top of her roughly $159,000 salary. In 2006, she received cash bonuses of $44,000, according to published reports cited by Dow Jones. An FDA spokesperson tells the wire service that Glavin will retire later this summer.

For the last several years, lawmakers have hammered the agency over what it calls excessive bonuses paid to senior FDA officials. Lawmakers have also questioned whether officials violated rules guiding the payment of bonuses, saying bonuses were given without records justifying the payments, according to Dow Jones.

John Dingell, the Michigan Democrat who chairs the House Committee on Energy and Commerce, two months ago wrote FDA commish Andy von Eschenbach for info on retention bonuses, performance bonuses and other compensation awards provided to FDA employees. In 2004, Congress expanded a cash bonus program to help the federal government retain federal employees, many of whom can make up to twice their salary in the private sector.

In a separate internal email Monday, Dow Jones writes, Andy announced that David Horowitz was named assistant commish for policy. Since 2005, Horowitz has served in the FDA’s regulatory affairs office as assistant commissioner for policy.